hydron;N'-naphthalen-1-ylethane-1,2-diamine;dichloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: hydron;N'-naphthalen-1-ylethane-1,2-diamine;dichloride
• 化学式: C12H16Cl2N2
• mdl: MFCD00012556
• 分子量: 259.17
• InChiKey: MZNYWPRCVDMOJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.64
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  38
• 氢给体数：
  4
• 氢受体数：
  2

ADMET

毒理性

• 非人类毒性摘录

N-(1-萘基)乙烯二胺二盐酸被国家毒理学计划评估其对果蝇黑腹菌的性连锁隐性致死突变的诱导作用。Canton-S野生型雄性果蝇被处理，处理浓度导致大约30%的死亡率。处理后，雄性果蝇分别与3组Basc处女雌性果蝇交配，以产生3窝用于分析的后代。通过注射(1500 ppm)或喂食(3500 ppm)测试的浓度在此分析中呈阴性。

N-(1-Naphthyl)ethylene Diamine Dihydrochloride was evaluated for the induction of sex-linked recessive lethal mutations in Drosophila melanogaster by the National Toxicology Program. Canton-S wild-type males were treated with concentrations that result in approximately 30% mortality. Following treatment, males were mated individually to 3 harems of Basc virgin females to produce 3 broods for analysis. The concentrations tested by injection (1500 ppm) or feeding (3500 ppm) were negative in this assay.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

致癌性证据等级：雄性大鼠：阴性；雌性大鼠：阴性；雄性小鼠：阴性；雌性小鼠：阴性。

... Levels of Evidence of Carcinogenicity: Male Rats: Negative; Female Rats: Negative; Male Mice: Negative; Female Mice: Negative.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

N-(1-萘基)乙烯二胺二盐酸被国家毒理学计划评估其对果蝇黑腹菌的性连锁隐性致死突变的诱导作用。Canton-S野生型雄性果蝇被处理以导致大约30%的死亡率。处理后，雄性果蝇分别与3组Basc处女雌性果蝇交配，以产生3窝用于分析的后代。通过注射(1500 ppm)或喂食(3500 ppm)的测试浓度在此测试中呈阴性。

N-(1-Naphthyl)ethylene Diamine Dihydrochloride was evaluated for the induction of sex-linked recessive lethal mutations in Drosophila melanogaster by the National Toxicology Program. Canton-S wild-type males were treated with concentrations that result in approximately 30% mortality. Following treatment, males were mated individually to 3 harems of Basc virgin females to produce 3 broods for analysis. The concentrations tested by injection (1500 ppm) or feeding (3500 ppm) were negative in this assay.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

致癌性证据等级：雄性大鼠：阴性；雌性大鼠：阴性；雄性小鼠：阴性；雌性小鼠：阴性。

... Levels of Evidence of Carcinogenicity: Male Rats: Negative; Female Rats: Negative; Male Mice: Negative; Female Mice: Negative.

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  2-amino-4-furan-2-yl-6-methanesulfinyl-pyrimidine-5-carbonitrile 、 hydron;N'-naphthalen-1-ylethane-1,2-diamine;dichloride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 以 乙二醇二甲醚 为溶剂， 生成 2-Amino-4-furan-2-yl-6-[2-(naphthalen-1-ylamino)-ethylamino]-pyrimidine-5-carbonitrile
  参考文献：
  名称：

  Adenosine receptor ligands and their use in the treatment of disease

  摘要：

  本发明涉及至少含有一个氮原子的环状杂环芳香化合物及其在制造药物治疗与腺苷受体调节剂相关的疾病中的应用，如阿尔茨海默病、帕金森病、神经保护、精神分裂症、焦虑、疼痛、呼吸功能障碍、抑郁症、哮喘、过敏反应、低氧、缺血、癫痫、物质滥用、镇静作用以及它们可能作为肌肉松弛剂、抗精神病药、抗癫痫药、抗惊厥药和心脏保护剂等方面具有活性。

  公开号：

  US20010027196A1
• 作为产物：
  描述：

  1-溴代萘 、 乙二胺 生成 hydron;N'-naphthalen-1-ylethane-1,2-diamine;dichloride
  参考文献：
  名称：

  KROUPA, JAROSLAV

  摘要：

  DOI：

文献信息

• [EN] S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES<br/>[FR] COMPOSÉS DE S-NITROSOMERCAPTO ET DÉRIVÉS APPARENTÉS
  申请人：GALLEON PHARMACEUTICALS INC

  公开号：WO2009151744A1

  公开（公告）日：2009-12-17

  The present invention is directed to mercapto-based and S- nitrosomercapto-based SNO compounds and their derivatives, and their use in treating a lack of normal breathing control, including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions.

  本发明涉及基于巯基和S-亚硝基巯基的SNO化合物及其衍生物，以及它们在治疗正常呼吸控制缺失方面的用途，包括治疗与睡眠、肥胖、某些药物和其他医疗状况相关的呼吸暂停和低通气。
• [EN] ALLOSTERIC HEMOGLOBIN MODIFIERS WITH NITRIC OXIDE RELEASING MOIETY<br/>[FR] MODIFICATEURS ALLOSTÉRIQUES DE L'HÉMOGLOBINE AVEC UNE PARTIE LIBÉRANT DE L'OXYDE NITRIQUE
  申请人：UNIV VIRGINIA COMMONWEALTH

  公开号：WO2015100235A1

  公开（公告）日：2015-07-02

  Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.

  变构血红蛋白（Hb）修饰剂是含有亚硝酸氧化物（NO）基团的血红蛋白，允许在体内释放NO。这些化合物保留了变构血红蛋白修饰剂的输送氧气能力，能够结合Hb并增强Hb输送氧气到细胞和组织的能力，同时也释放NO基团中的NO。还提供了输送氧气和/或NO到细胞和组织的方法。
• [EN] DUAL ACTION NITRIC OXIDE DONORS AND THEIR USE AS ANTIMICROBIAL AGENTS<br/>[FR] DONNEURS D'OXYDE NITRIQUE À DOUBLE ACTION ET LEUR UTILISATION COMME AGENTS ANTIMICROBIENS
  申请人：NEWSOUTH INNOVATIONS PTY LTD

  公开号：WO2014071457A1

  公开（公告）日：2014-05-15

  The present invention relates generally to conjugates comprising a nitric oxide donor and an acyl homoserine lactone, fimbrolide, fimbrolide derivative, dihydropyrrolone or indole, and to the use of such conjugates as antimicrobial agents.

  本发明涉及一般地与一氧化氮供体和酰基同源丁氨酸内酯、菲螺啉、菲螺啉衍生物、二氢吡咯酮或吲哚构成的结合物，以及将这些结合物用作抗微生物剂的用途。
• Triamine derivatives and their acid-addition salts
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0443862A1

  公开（公告）日：1991-08-28

  A triamine derivative of the formula (I) wherein Ar¹ and Ar² are carbocyclic or heterocyclic single ring or fused ring aromatic groups, R¹, R² and R³ are hydrogen, lower alkyl, aryl aryl-alkyl, aryl-alkyloxycarbonyl, alkyloxycarbonyl or acyl, and A¹ and A² are lower alkylene groups optionally substituted by oxo, exhibits a high N-methyl-D-aspartic acid (NMDA) receptor antagonistic effect and are therefore useful as a medicine for nerve degeneration diseases.

  式(I)的三胺衍生物，其中Ar¹和Ar²是碳环或杂环的单环或融合环芳香基团，R¹、R²和R³是氢、低碳基、芳基芳基-烷基、芳基-烷氧羰基、烷氧羰基或酰基，A¹和A²是可选择地被氧代取代的低碳烯基基团，表现出高N-甲基-D-天冬氨酸（NMDA）受体拮抗作用，因此可用作治疗神经退行性疾病的药物。
• [EN] ALLOSTERIC INHIBITORS OF ATYPICAL PROTEIN KINASES C<br/>[FR] INHIBITEURS ALLOSTÉRIQUES DE PROTÉINES KINASES C ATYPIQUES
  申请人：UNIV SAARLAND

  公开号：WO2015075051A1

  公开（公告）日：2015-05-28

  The invention provides specific small molecule compounds that allosterically regulate the activity of atypical protein kinase C, their use as a medicament, and their use in the treatment and prevention of allergic, inflammatory and autoimmune disorders, cancer, hyperproliferation, sepsis, viral and protozoan infections, dementing diseases, metabolic, sclerotic and osteoporotic disorders.

  这项发明提供了特定的小分子化合物，可以对非典型蛋白激酶C的活性进行变构调节，其用作药物，并用于治疗和预防过敏、炎症和自身免疫性疾病、癌症、过度增殖、败血症、病毒和原虫感染、痴呆症、代谢性疾病、硬化和骨质疏松症。

表征谱图